Current Diagnosis and Treatment Modalities for Ovarian Cancer

  • Peter E. Schwartz
Part of the Cancer Treatment and Research book series (CTAR, volume 107)

Abstract

Ovarian cancer is the major pelvic cancer health hazard for women. In 2000, the American Cancer Society estimates that 23,100 new ovarian cancer cases will be diagnosed and 14,000 women will have died of ovarian cancer (1). It is the fifth most common cancer in American women but the fourth most common cause of cancer death (1). The high mortality rate is due in part to a lack of obvious early warning symptoms, unavailability of sensitive early detection techniques and therapy of limited effectiveness. Despite improvements in management of women with epithelial ovarian cancer, the overall survival for this disease has been unchanged for at least the last 20 years (2). This chapter will concentrate on advances in the diagnosis and management of epithelial ovarian cancers, the form of ovarian cancer that represents at least 90% of all ovarian malignancies.

Keywords

Ovarian Cancer Clin Oncol Epithelial Ovarian Cancer Cytoreductive Surgery Intraperitoneal Chemotherapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Landis SH, Murray T, Bolden S, et al. Cancer statistics, 2000. CA Cancer J Clin 2000; 50: 8–13.Google Scholar
  2. 2.
    Yanik R. Ovarian cancer: Age contrasts in incidence, histology, disease stage at diagnosis and mortality. Cancer 1993; 71: 517–523.CrossRefGoogle Scholar
  3. 3.
    Goff BA, Mandel LS, Muntz HG, Melancon CH. Ovarian cancer diagnosis: Results of a National Ovarian Cancer Survey. Gynecol Oncol 2000; 76: 231.Google Scholar
  4. 4.
    Bast RC Jr, Klug T.1, St John E, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983; 309: 883–7PubMedCrossRefGoogle Scholar
  5. 5.
    Schwartz PE, Chambers JT, Taylor KJW, et al. Early detection of ovarian cancer: background, rationale and structure of the Yale Early Detection Program. Yale J Biol Med 1991; 64: 557–71.PubMedGoogle Scholar
  6. 6.
    Karlan BY, Raffel LJ, Crvenkovic G, et al. A multidisciplinary approach to the early detection of ovarian carcinoma: rationale, protocol design and early results. Am J Obstet Gynecol 1993; 169: 494–501.PubMedGoogle Scholar
  7. 7.
    Muto M, Cramer DW, Brown DL, et al. Screening for ovarian cancer: the preliminary experience of a familial ovarian cancer center. Gynecol Oncol 1993; 51: 12–20.PubMedCrossRefGoogle Scholar
  8. 8.
    Jacobs I, Davies AP, Bridges J, et al. Prevalence screening for ovarian cancer in postmenopausal women by CA-125 measurement and ultrasonography. BMJ 1993; 306: 1030–4.PubMedCrossRefGoogle Scholar
  9. 9.
    Xu Y, Shen Z, Wiper D, et al. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA 1998; 280: 719–723.PubMedCrossRefGoogle Scholar
  10. 10.
    Taylor KJW, Schwartz PE. Screening for early ovarian cancer. Radiology 1994; 192: 1–10.PubMedGoogle Scholar
  11. 11.
    Campbell S, Bhan V, Royston P, et al. Transabdominal ultrasound screening for ovarian cancer. BMJ 1989; 299: 1363–7.PubMedCrossRefGoogle Scholar
  12. 12.
    Campbell S, Bourne T, Bradley E. Screening for ovarian cancer by transvaginal sonography and colour Doppler. Eur J Obstet Gynecol Reprod Biol 1992; 49: 33–34.CrossRefGoogle Scholar
  13. 13.
    Van Nagell JR, Higgins RV, Donaldson ES, et al. Transvaginal sonography as a screening method for ovarian cancer: a report of the first 1000 cases screened. Cancer 1990; 65: 573–7.PubMedCrossRefGoogle Scholar
  14. 14.
    DePriest PD, Gallion HM, Paulik EJ, Kryscio RJ, Van Nagell JR Jr. Transvaginal sonography as a screening method for the detection of early ovarian cancer. Gynecol Oncol 1997; 65: 408–417.PubMedCrossRefGoogle Scholar
  15. 15.
    Childers JM, Lang J, Surwit EA, Hatch KO. Laparoscopic surgical staging of ovarian cancer. Gynecol Oncol 1995; 59: 25–33.PubMedCrossRefGoogle Scholar
  16. 16.
    Griffiths CT. Surgical resection of tumor bulk in the primary treatment of ovarian cancer. Mongr Natl Cancer Inst. 1975; 45: 101–104.Google Scholar
  17. 17.
    Hoskins WJ. Surgical staging and cytoreduction surgery of epithelial ovarian cancer. Cancer 1993; 71: 1534–40.PubMedCrossRefGoogle Scholar
  18. 18.
    Shelley WE, Carmichael JC, Brown LB, et al. Adriamycin and cis-platinum in the treatment of stage III and IV epithelial ovarian cancer. Gynecol Oncol 1988; 29: 208221.Google Scholar
  19. 19.
    Schwartz PE, Chambers JT, Kohom EI, Chambers SK, Weitzman H, Voynick M, MacLusky N, Naftolin F. Tamoxifen in combination chemotherapy with cytotoxic chemotherapy in advanced epithelial ovarian cancer: A prospective randomized trial. Cancer 1989; 63: 1074–1078.Google Scholar
  20. 20.
    Le T, Krepart GV, Lotocki RJ, Hewood MS. Does debulking surgery improve survival in biologically aggressive ovarian cancer? Gynecol Oncol 1997; 67: 208–14.PubMedCrossRefGoogle Scholar
  21. 21.
    Adelson MD. Cytoreduction of diaphragmatic metastases using the Cavitron ultrasound surgical aspirator. Gynecologic Oncol 1991; 41: 220–222.CrossRefGoogle Scholar
  22. 22.
    Farghaly SA. Surgical techniques for cytoreduction in advanced ovarian malignancy. Am J Obstet Gynecol 1993; 168: 736.PubMedGoogle Scholar
  23. 23.
    Fanning J, Hilgers RO. Loop electrical excision procedure for intensified cytoreduction of ovarian cancer. Gynecol Oncol 1995; 57: 188–90.PubMedCrossRefGoogle Scholar
  24. 24.
    Hoskins WJ, Bundy BN, Thigpen JT, Omura GA. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: A Gynecologic Oncology Group Study. Gynecol Oncol 1992; 47: 56166.CrossRefGoogle Scholar
  25. 25.
    Scarabelli C, Gallo A, Zarrellia, Visentin C, Campagnutta E. Systematic pelvic and para-aortic lymphadenectomy during cytoreductive surgery in advanced ovarian cancer: Potential benefit on survival. Gynecol Oncol 1995; 56: 328–37.PubMedCrossRefGoogle Scholar
  26. 26.
    Hacker NF. Systematic pelvic and para-aortic lymphadenectomy for advanced ovarian cancer-therapeutic advance or surgical folly? Gynecol Oncol 1995; 56: 325–7.PubMedCrossRefGoogle Scholar
  27. 27.
    Chambers JT, Merino MJ, Kohom EI, Schwartz PE. Borderline ovarian tumors. Am J Obstet Gynecol 1988; 159: 1088–1094.PubMedGoogle Scholar
  28. 28.
    Kaem J, Trope CG, Abeler V. A retrospective study of 370 borderline tumors of the ovary treated at the Norwegian Radium Hospital 1970–1982. A review of clinico-pathological features and treatment modalities. Cancer 1993; 71: 1810–20.CrossRefGoogle Scholar
  29. 29.
    Bell DA, Weinstock MA, Scully RE. Peritoneal implants of ovarian serous borderline tumors: Histologic features and prognosis. Cancer 1988; 62: 2212–22.PubMedCrossRefGoogle Scholar
  30. 30.
    Lim-Tan SK, Cajigas HB, Scully RE. Ovarian cystectomy for serous borderline tumors. A follow-up study of 35 cases. Obstet Gynecol 1988; 72: 775–80.PubMedGoogle Scholar
  31. 31.
    Bell DA, Scully RE. Ovarian serous borderline tumors with stromal microinvasion: A report of 21 cases. Hum Path 1990; 21: 397–403.PubMedCrossRefGoogle Scholar
  32. 32.
    Ahmed FY, Wiltshaw E, A’Hem RP, et al. Natural history and prognosis of untreated stage I epithelial ovarian cancer. J Clin Oncol 1996; 14: 2968–2975.PubMedGoogle Scholar
  33. 33.
    Young RC, Walton LA, Ellenberg SS, et al. Adjuvant therapy in stage I and stage II epithelial ovarian cancer: Results of two prospective randomized trials. N Engl J Med 1990; 322: 1021–7.PubMedCrossRefGoogle Scholar
  34. 34.
    Monga M, Carmichael JA, Shelley WE, et al. Surgery without adjuvant chemotherapy for early epithelial ovarian carcinoma after comprehensive surgical staging. Gynecol Oncol 1991; 43: 195–197.PubMedCrossRefGoogle Scholar
  35. 35.
    Young RC, Brady MF, Nieberg RM, et al. Randomized clinical trial of adjuvant treatment of women with early (FIGO I-IIA high risk) ovarian cancer. Int J. Gynecol Cancer 1997; 7 (suppl 2): 17.Google Scholar
  36. 36.
    Bolis G, Colombo N, Pecorelli S, et al. Adjuvant treatment for early epithelial ovarian cancer: results of two randomized clinical trials comparing cisplatin to no further treatment or chromic phosphate. Ann Oncol 1995; 6: 887–893.PubMedGoogle Scholar
  37. 37.
    Columbo N, Chiari S, Maggioni A, Bocciolone E, Tom V, Mangioni C. Controversial issues in the management of early ovarian cancer: Conservative surgery and role of adjuvant therapy. Gynecol Oncol 1994; 55: S47–51.CrossRefGoogle Scholar
  38. 38.
    Kaufman RJ. Management of advanced ovarian carcinoma. Med Clinics N. Amer 1966; 50: 845–856.Google Scholar
  39. 39.
    Wharton JT, Edward CL, Rutledge FN. Long-term survival after chemotherapy for advanced epithelial ovarian carcinoma. AM J Obstet Gynecol 1984; 148:997-.Google Scholar
  40. 40.
    Goodman HM, Harlow BL, Sheets EE, et al. The role of cytoreductive surgery in the management of stage IV epithelial ovarian carcinoma. Gynecol Oncol 1992; 46: 36771.CrossRefGoogle Scholar
  41. 41.
    Liu P, Benjamin I, Morgan M, et al. Effect of surgical debulking on survival in Stage IV ovarian cancer. Gynecol Oncol 1997; 64: 4–8.PubMedCrossRefGoogle Scholar
  42. 42.
    Curtin JP, Malik R, Venkatraman ES, Barakat RR, Hoskins WJ. Stage IV ovarian cancer: impact of surgical debulking. Gynecol Oncol 1997; 64: 9–12.PubMedCrossRefGoogle Scholar
  43. 43.
    Munkarah AR, Hallum AV III, Morris M, et al. Prognostic significance of residual disease in patients with Stage IV epithelial ovarian cancer. Gynecol Oncol 1997; 64: 13–17.PubMedCrossRefGoogle Scholar
  44. 44.
    Omura GA, Bundy BN, Berek JS, Curry S, Delgado G, Mortel R. Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: A Gynecologic Group study. 1989; 7: 457–65.Google Scholar
  45. 45.
    Alberts DS, Green S, Hannigan EV, et al. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: Final report by the Southern Oncology Group of a phase III randomized trial in stage III and IV ovarian cancer. J Clin Oncol 1992; 10: 706–17. [Erratum, J Clin Oncol 1992; 10:1505.]Google Scholar
  46. 46.
    Swenerton K, Jeffrey J, Stuart G, et al. Cisplatin-cyclophosphamide versus carboplatincyclophosphamide in advanced ovarian cancer: A randomized phase III study of the National Cancer Institute of Canada Clinical Trial Group. J Clin Oncol 1992; 10: 7 1826.Google Scholar
  47. 47.
    Bertelsen K, Jakobsen A, Stroyer I, et al. A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin and cisplatin in advanced epithelial ovarian cancer: A Danish Ovarian Study Group trial (DACOVA). Gynecol Oncol 1993; 49: 30–36.PubMedCrossRefGoogle Scholar
  48. 48.
    Hakes TB, Chalas E, Hoskins WJ, et al. Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin and cisplatin in advanced ovarian carcinoma. Gynecol Oncol 1992; 42: 284–289.CrossRefGoogle Scholar
  49. 49.
    McGuire WP, Hoskins WJ, Brady MF, et al. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 1995; 13: 1589–1599.PubMedGoogle Scholar
  50. 50.
    McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer. N Engl J Med 1996; 334: 1–6.PubMedCrossRefGoogle Scholar
  51. 51.
    Muggia FM. Braly PS, Sutton G, et al. Phase III of cisplatin (P) or paclitaxel (T) versus their combination in suboptimal Stager III and IV epithelial ovarian cancer (EOC). Gynecologic Oncology Group study #132. Proc ASCO 1997; 16: 352a.Google Scholar
  52. 52.
    Eisenhauer EE, Ten Bokkel-Huinink WW, Swenerton KD, et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High dose versus low-dose and long versus short infusion. J Clin Oncol 1994; 12: 2654–2666.PubMedGoogle Scholar
  53. 53.
    Rosman M, Hayden CL, Thiel RP, Chambers S, Chambers J, Kohorn EI, Schwartz PE. Prognostic indicators for poor risk epithelial ovarian cancer. Cancer 1994; 74: 1323–28.PubMedCrossRefGoogle Scholar
  54. 54.
    Schwartz PE, Smith JP. Second-look operations in ovarian cancer. Am J Obstet Gynecol 1980; 138: 1124–1130.PubMedGoogle Scholar
  55. 55.
    Stanhope CR, Smith JP, Rutledge F. Second trial drugs in ovarian cancer. Gynecol Oncol 1977; 5: 52–8.PubMedCrossRefGoogle Scholar
  56. 56.
    Chambers SK, Chambers JT, Kohorn EI, Lawrence R, Schwartz PE. Evaluation of the role of second-look surgery in ovarian cancer. Obstet Gynecol 1988; 72: 404–408.PubMedGoogle Scholar
  57. 57.
    Rubin SC, Hoskins WJ, Saigo PE, et al. Prognostic factors for recurrence following negative second-look laparotomy in ovarian cancer patients treated with platinum-based chemotherapy. Gynecol Oncol 1991; 42: 137–41.PubMedCrossRefGoogle Scholar
  58. 58.
    Casey AC, Fartas-Eisner R, Pisani AL, et al. What is the role of reassessment laparoscopy in the management of gynecologic cancers in 1995? Gynecol Oncol 1996; 60: 454–461.PubMedCrossRefGoogle Scholar
  59. 59.
    Levin L, Hryniuk WM. Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. J. Clin Oncol 1987; 5: 756–67.PubMedGoogle Scholar
  60. 60.
    Kaye SB, Paul J, Cassidy CR, et al. Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. J Clin Oncol 1996; 14: 2113–2119.PubMedGoogle Scholar
  61. 61.
    McGuire WP. Primary treatment of epithelial ovarian malignancies. Cancer 1993; 71: 1541–50.PubMedCrossRefGoogle Scholar
  62. 62.
    Gore M, Mainwaring P, A’Hem R, et al. Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer. J Clin Oncol 1998; 16: 2426–2434.PubMedGoogle Scholar
  63. 63.
    Sarosy G, Kohn E, Stone DA, et al. Phase I study of Taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer. J Clin Oncol 1992; 10: 1165–1170.PubMedGoogle Scholar
  64. 64.
    Lund B, Hansen M, Hansen OP, Hansen HH. High-dose platinum consisting of combined carboplatin and cisplatin in previously untreated ovarian cancer patients with residual disease. J Clin Oncol 1989; 7: 1469–73.PubMedGoogle Scholar
  65. 65.
    Lund B, Hansen M, Hansen OP, Hansen HH. Combined high-dose carboplatin and cisplatin and ifosfamide in previously untreated ovarian cancer patients with residual disease. J Clin Oncol 1990; 8: 1226–30.PubMedGoogle Scholar
  66. 66.
    Legros M, Dauplat J, Fleury J, et al. High-dose chemotherapy with hematopoietic rescue in patients with stage III to IV ovarian cancer: long-term results. J Clin Oncol 1997; 15: 1302–8.PubMedGoogle Scholar
  67. 67.
    Aghajanian C, Fennelly D, Shapiro F, et al. Phase II study of “dose-dense” high-dose chemotherapy treatment with peripheral-blood progenitor-cell support as primary treatment for patients with advanced ovarian cancer. J Clin Oncol 1998; 16: 1852.PubMedGoogle Scholar
  68. 68.
    Markman M, Rothman R, Hakes T, Reichman B, Hoskins W, Rubin S, Jones W, Almandrone’s L, Lewis JL, Jr. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991; 9: 389–93.PubMedGoogle Scholar
  69. 69.
    Thigpen JT, Vance RB, Khansur T. Second-line chemotherapy for recurrent carcinoma of the ovary. Cancer 1993; 71: 1559–64.PubMedCrossRefGoogle Scholar
  70. 70.
    Stiff PJ, Bayer R, Kerger C, et al. High-dose chemotherapy with autologous transplantation for persistent/relapsed ovarian cancer: a multivariate analysis of survival for 100 consecutively treated patients. J Clin Oncol 1997; 15: 1309–17.PubMedGoogle Scholar
  71. 71.
    Kudelka AP, Tresukosol D, Edwards CL, et al. Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol 1996; 14: 1552–1557.PubMedGoogle Scholar
  72. 72.
    ten Bokkel-Huinink W, Gore M. Carmichael J, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997; 15: 2183–93.PubMedGoogle Scholar
  73. 73.
    Hochster H, Wadler S, Runowitz C, et al. Activity and pharmacodynamics of 21-day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy. J Clin Oncol 1999; 17: 2553.Google Scholar
  74. 74.
    Bajetta E, DiLeo A, Biganzoli L, et al. Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: Activity in platinum-resistant disease. J Clin Oncol 1996; 14: 2546–2551.PubMedGoogle Scholar
  75. 75.
    DeLena M, Lorusso V, Bottalico C, et al. Revertant and potentiating activity of lonidamine in patients with ovarian cancer previously treated with platinum. J Clin Oncol 1997; 15: 3208–3213.Google Scholar
  76. 76.
    Muggia FM, Hainsworth JD, Jeffer S, et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: anti-tumor activity and toxicity modification by liopsomal encapsulation. J Clin Oncol 1997; 15: 987–93.PubMedGoogle Scholar
  77. 77.
    Kaufmann M, von Minckwitz G. Gemcitabine in ovarian cancer: An overview of safety and efficacy. Eur J Cancer 1997; 33: 531–33.CrossRefGoogle Scholar
  78. 78.
    Segna RA, Dottino PR, Mandeli SP, Konsker K, Cohen CJ. Secondary cytoreduction for ovarian cancer following cisplatin therapy. J Clin Oncol 1993; 11: 434–39.PubMedGoogle Scholar
  79. 79.
    van der Burg MEL, van Lent M, Buyse M, et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N Engl J Med 1995; 332: 629–634.PubMedCrossRefGoogle Scholar
  80. 80.
    van der Burg, MEL, van Lent M, Kobierska A, et al. After 6 years follow-up intervention debulking surgery remains an independent prognostic factor for survival in advanced epithelial ovarian cancer: An EORTC Gynecologic Cancer Cooperative Group study. Int J Gynecol Cancer 1997; 7 (suppl 2): 28.Google Scholar
  81. 81.
    Howell SB, Zimm S, Markman M, et al. Long-term survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy. J Clin Oncol 1987; 5: 1607–12.PubMedGoogle Scholar
  82. 82.
    Markman M, Berek JS, Blessing JA, McGuire WP, Bell J, Homesley HD. Characteristics of patients with small-volume residual ovarian cancer unresponsive to cisplatin-based ip chemotherapy: Lessons learned from a Gynecologic Oncology Group phase II trial of ip cisplatin and recombinant alpha-interferon. Gynecol Oncol 1992; 45: 3–8.PubMedCrossRefGoogle Scholar
  83. 83.
    Kirmani S, Braly PS, McClay EF, et al. A comparison of intravenous versus intraperitoneal chemotherapy for the initial treatment of ovarian cancer. Gynecol Oncol 1994; 54: 338–44.PubMedCrossRefGoogle Scholar
  84. 84.
    Alberts DS, Liu PY, Hannigan EV, et al. Phase III study of intraperitoneal (IP) cisplatin (CDDP)/intravenous (IV) cyclophosphamide (CPA) vs. IV CDDP/IV CPA in patients (PTS) with optimal disease stage III ovarian cancer: A SWOG-GOG-ECOG intergroup study (int 0051). Proceed ASCO 1995; 14: 273.Google Scholar
  85. 85.
    Stewart JA, Belinson JL, Moore AL, et al. Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer. Cancer Res 1990; 50: 6302–10.PubMedGoogle Scholar
  86. 86.
    Stewart JSW, Hird V, Snook D, et al. Intraperitoneal yttrium-90-labeled monoclonal antibody in ovarian cancer. J Clin Oncol 1990; 8: 1941–50.PubMedGoogle Scholar
  87. 87.
    Hird V, Maraveyas A, Senook D, et al. Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody. Br J Cancer 1993; 68: 403–6.PubMedCrossRefGoogle Scholar
  88. 88.
    Pujade-Lauraine E, Guastalla JP, Colombo N, et al. Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy. J Clin Oncol 1996; 14: 343–350.PubMedGoogle Scholar
  89. 89.
    Berek, JS, Markman M, Stonebraker B, et al. Intraperitoneal interferon a in residual ovarian carcinoma: A phase II Gynecologic Oncology Group study. Gynecol Oncol 1999; 75: 10–14.PubMedCrossRefGoogle Scholar
  90. 90.
    Berek JS, Markman M, Blessing JA, et al. Intraperitoneal a interferon alternating with cisplatin in residual ovarian carcinoma: A phase II Gynecologic Oncology Group study. Gynecol 1999; 74: 48–52.CrossRefGoogle Scholar
  91. 91.
    Nelson BE, Rosenfield AT, Schwartz PE. Preoperative abdominopelvic computed tomography prediction of optimal cytoreduction in epithelial ovarian carcinoma. J Clin Oncol 1993; 11: 166–72.PubMedGoogle Scholar
  92. 92.
    Schwartz PE, Rutherford TJ, Chambers JT, et al. Neoadjuvant chemotherapy for advanced ovarian cancer: Long-term survival. Gynecol Oncol 1999; 72: 93–99.PubMedCrossRefGoogle Scholar
  93. 93.
    Surwit E, Childers J, Atlas I, et al. Neoadjuvant chemotherapy for advanced ovarian cancer. Int J Gynecol Cancer 1996; 6: 356–366.CrossRefGoogle Scholar
  94. 94.
    Dorigo O, Berek JS. Gene therapy for ovarian cancer: development of novel treatment strategies. Int J Gynecol Cancer 1997; 7: 1–13.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2002

Authors and Affiliations

  • Peter E. Schwartz
    • 1
  1. 1.Department of Obstetrics and GynecologyYale University School of MedicineNew HavenUSA

Personalised recommendations